Top 3 BIO STOCKS To Watch This Week 12/9/19

Good afternoon everyone,

 HELLO & WELCOME!!! It has been a while but I owe you guys/gals at least 3 bio tickers for this week!. We will be covering what Bio Pharmaceuticals are on the radar for this week in this blog.

So without further ado, lets see what is cooking this week!


1. Veru Inc.($VERU) is an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer. 

  • Phase 2 data due fall of 2019 for Zuclomiphene citrate.

What is Zuclomiphene Citrate?
Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being evaluated in a Phase 2 trial to treat hot flashes, a common side effect caused by androgen deprivation therapy (ADT) in men with advanced prostate cancer.

Yearly Chart:

My Opinion: Looking at the chart, this has been knocking the 52 high of $2.49, with a catalyst coming up. Any news will drive this higher and chart shows history of spiking on Press Releases (PR), like always trade with a PLAN!!!


2. Mustang Bio ($MBIO) is a clinical-stage bio-pharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S

  • Phase 1 data to be presented at ASH 12/8/19 (Today) for MB-106.
  • Possible PR tomorrow or some time this week to get more volume

What is MB-106?

MB-106 is for the treatment of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Yearly Chart:

My Opinion: MBIO has the history of getting massive volume on news, and shortly selling off after. This is not one to 'Hold & Hope' but strictly stick to your strategy and execute your plan accordingly.


3. PDS Biotechnology ($PDSB) is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

RED FLAG: 1 for 20 Reverse Split ~ 03/18/2019

  • Extreme Low Floater
  • Phase 2 trial planned for 1Q 2020 with interim data due 2Q 2021.
  • Phase 1 trial data to be presented at ASH 12/8/19 (Today) for PDS0101
  • Possible PR sometime this week.

What is PDS0101?
On October 28, 2019, PDS entered into an amendment to the clinical trial collaboration agreement with a subsidiary of Merck (known as MSD outside the United States and Canada) to evaluate the combination of PDS's lead Versamune®-based immunotherapy, PDS0101, with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in a Phase II clinical trial.

The planned clinical trial will now evaluate the efficacy and safety of the combination as a first-line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection and is expected to be initiated in the first quarter of 2020.  

The modification to the clinical trial design to evaluate PDS0101 in combination with KEYTRUDA® as first-line treatment comes as a result of Merck’s recent approval by the FDA on June 10, 2019 for first line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) using KEYTRUDA® in combination with platinum and fluorouracil (FU) for all patients and as a single agent for patients whose tumors express PD-L1 as determined by an FDA-approved test.

My Opinion: *EDIT* The Company has already closed the offering. The chart looks very bullish leading into the new year. The company has a couple of things in its pipeline. 

Yearly Chart:


DISCLAIMER: Please note that I do not ask for any information. I always encourage people to trade ONLY what you understand and never based on anyone's opinion. My posts are for educational purposes only. The stock market is known to make people bag holders, get a head of the whales and always do your DUE DILIGENCE!

1 comment

  • Propecia Cost Rite Aid Edgedeerturo cheapest cialis generic online emamma Pyridium Online No Prescription Needed


Leave a comment